Uses of ion channel modulating compounds
View Patent ↗Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
1. A method for treating a human subject undergoing arrhythmia, the method comprising administering to the subject an amount of an ion channel modulating compound in one or more intravenous doses of a formulation, wherein each dose of the formulation independently comprises an ion channel modulating compound of formula
including isolated enantiomeric, diastereomeric and geometric isomers thereof and mixtures thereof, or a solvate or pharmaceutically acceptable salt thereof;
wherein R 4 and R 5 are independently selected from hydrogen, hydroxy and C 1 -C 6 alkoxy; and
wherein the amount of ion channel modulating compound administered to the subject produces in the blood plasma of the subject a total concentration of the ion channel modulating compound with a concentration of greater than about 0.1 μg/ml for some time.
2. The method of claim 1 , wherein the total concentration of the ion channel modulating compound has a C max of greater than about 0.1 μg/ml.
3. The method of claim 2 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a C max of between about 0.3 μg/ml and about 20 μg/ml.
4. The method of claim 2 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a C max of between about 0.3 μg/ml and about 15 μg/ml.
5. The method of claim 1 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject is greater than 0.1 μg/ml for a period of time of at least about 10 hours.
6. The method of claim 1 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject is greater than 1.0 μg/ml for a period of time of at least about 2 hours.
7. The method of claim 1 , wherein the ion channel modulating compound is administered in two or more doses.
8. The method of claim 1 , wherein the method comprises administering to the subject one or two doses of the formulation, and wherein each dose of the formulation comprises a monohydrochloride salt of the formula
9. The method claim 1 , wherein the formulation is an isotonic solution of the ion channel modulating compound.
10. The method of claim 2 , wherein the arrhythmia is an atrial arrhythmia.
11. The method of claim 10 , wherein the arrhythmia is an atrial fibrillation.
12. The method of claim 1 , wherein the arrhythmia is selected from the group comprising ventricular tachycardia, ventricular fibrillation, premature ventricular contractions, supraventricular tachycardia, Wolff-Parkinson-White Syndrome, atrial fibrillation, and premature supraventricular contractions, or wherein the arrhythmia is associated with Long Q-T Syndrome or sick sinus syndrome.
13. A method of administering a therapeutically effective amount of an ion channel modulating compound of formula
including isolated enantiomeric, diastereomeric and geometric isomers thereof and mixtures thereof, or a solvate or pharmaceutically acceptable salt thereof;
wherein R 4 and R 5 are independently selected from hydrogen, hydroxy and C 1 -C 6 alkoxy;
to a human subject for the treatment of arrhythmia, wherein the method comprises administering to the human subject a first dosage amount of between about 0.1 mg/kg and about 10 mg/kg of the ion channel modulating compound; and, after a time period sufficient to determine the therapeutic effectiveness of the first dosage amount, optionally administering a second dosage amount of between about 0.1 mg/kg and about 10 mg/kg of the ion channel modulating compound, which produces in the blood plasma of the human subject a total concentration of the ion channel modulating compound of greater than about 0.1 μg/ml for at least some time.
14. The method of claim 13 , which produces a C max of the ion channel modulating compound in the blood plasma of the human subject of between about 0.3 μg/ml and about 20 μg/ml.
15. The method of claim 13 , which produces a C max of the ion channel modulating compound in the blood plasma of the human subject of between about 0.3 μg/ml and about 15 μg/ml.
16. The method of claim 13 , which produces a total concentration of the ion channel modulating compound in the blood plasma of the human subject greater than about 0.1 μg/ml for a period of time of at least about 10 hours.
17. The method of claim 13 , which produces a total concentration of the ion channel modulating compound in the blood plasma of the human subject greater than about 0.1 μg/ml for a period of time of at least about 2 hours.